Latest filing published 25 Mar 2026 for Swedish Orphan Biovitrum AB (publ), €84k.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
David Meek: trading record in brief
David Meek (chief executive) discloses dealings in Swedish Orphan Biovitrum AB (publ) to Finansinspektionen. We count 2 filings, every one of them for a trade on 23 March 2026.
Purchases make up the whole of the open-market record (2 purchases, €130k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
Most recently, on 25 March 2026, the filings show an open-market purchase worth €84k in Swedish Orphan Biovitrum AB (publ). These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.
Companies and markets linked to David Meek
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,477 shares@ US$39.1664.5% of flowAktieISIN SE0000872095FI:csv-3474903129900f1e3db5Canonical exit: 21 Jun 2026 (T+90)
- 1,366 shares@ US$39.1635.5% of flowAktieISIN SE0000872095FI:A003X324-1Canonical exit: 21 Jun 2026 (T+90)
2 of 2 declarations